• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine plus cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Bekai.pdf
    Size:
    83.34Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Bekaii-Saab, T.
    Valle, Juan W
    Van Cutsem, E.
    Rimassa, L.
    Furuse, J.
    Ioka, T.
    Macarulla, T.
    Bridgewater, J.
    Wasan, H.
    Borad, M.
    Vogel, A.
    Lihou, C.
    Zhen, H.
    Jiang, P.
    Langmuir, P
    Melisi, D.
    Show allShow less
    Affiliation
    Mayo Clinic Phoenix, Phoenix, United States
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background:For advanced cholangiocarcinoma, standard-of-carefirst-line systemictreatment is gemcitabine + cisplatin. Activating genetic alterations in patients withintrahepatic cholangiocarcinoma provide potential therapeutic targets. Fibroblastgrowth factor receptor (FGFR) 2 gene fusions or rearrangements drive chol-angiocarcinoma tumorigenesis and occur in 10e16% of patients, being almostexclusively confined to patients with intrahepatic cholangiocarcinoma. In phase 2,pemigatinib (INCB054828), a selective, potent, oral FGFR1e3 inhibitor elicited anobjective response rate (ORR) of 35.5%, a median progression-free survival (PFS) of6.9 months, a median duration of response (DOR) of 9.1 months, and a diseasecontrol rate (DCR) of 82.0% in previously treated, locally advanced, or metastaticcholangiocarcinoma with FGFR2 rearrangements (FIGHT-202; NCT02924376). FIGHT-302, a randomized, open-label, phase 3 study, will evaluate efficacy and safety offirst-line pemigatinib vs gemcitabine + cisplatin in unresectable/metastatic chol-angiocarcinoma with documented FGFR2 fusions or rearrangements (NCT03656536).Trial design:Eligible patients are adults who have confirmed, radiographicallymeasurable/evaluable (per Response Evaluation Criteria in Solid Tumors [RECIST]v1.1) unresectable/metastatic cholangiocarcinoma with documented FGFR2 fusionsor rearrangements, received no prior systemic therapy for advanced disease 5.5 mg/dL) or grade 2 treatment-related adverse events (cycle 1). Hyperphosphatemia willbe managed with diet modifications, phosphate binders, diuretics, or dose adjust-ments. Treatment will continue until disease progression or unacceptable toxicity.Primary endpoint is PFS (independent review). Secondary endpoints are ORR, overallsurvival (OS), DOR, DCR, safety, and quality of life. Exploratory endpoints includeevaluation of the relationship between specific FGFR2 alterations and clinical activity(assessed by their association with PFS, OS and ORR), and the relationship betweenbiomarkers and clinical activity that may be indicative of clinical response, safety,pharmacodynamics and/or pemigatinib mechanism of action. Sites are open acrossUS, Europe and Asia.
    Citation
    Bekaii-Saab T, Valle J, Van Cutsem E, Rimassa L, Furuse J, Ioka T, et al. P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement. Annals of Oncology. 2021 Jul;32:S137.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624427
    DOI
    10.1016/j.annonc.2021.05.168
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.05.168
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.05.168
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.